and Regulatory Strategy

Introduction

Drug-drug interactions (DDIs) represent a major challenge in clinical pharmacology, especially during the early development phase. In Phase 1 trials, understanding how a new investigational product (IP) behaves when co-administered with other commonly used medications is crucial for patient safety and dose optimization. DDI studies identify whether a drug is a perpetrator (causing an interaction) or a victim (affected by another drug). This tutorial outlines the essential components of DDI study design in Phase 1, including regulatory guidance, PK/PD endpoints, selection of probe substrates, and data interpretation.

Why DDI Studies in Phase 1?

DDI studies in Phase 1 are designed to anticipate and mitigate risks before exposure in vulnerable patients or broader populations. Such studies help determine:

• If dose adjustments are needed when co-administered with other drugs
• Which metabolic pathways are involved (e.g., CYP enzymes, transporters)
• Whether there are risks of increased toxicity or decreased efficacy

Regulatory Framework for DDI Studies

FDA Guidance

• FDA (2020): “Clinical Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions”
• Recommends a tiered approach starting from in vitro findings to in vivo studies
• Strong emphasis on mechanistic understanding and modeling

EMA Guideline

• EMA: “Guideline on the investigation of drug interactions”
• Promotes PBPK modeling to reduce the need for unnecessary clinical trials
• Recommends dedicated DDI studies for drugs with narrow therapeutic index

CDSCO India

• DDI studies must be included in the Phase 1 protocol when prior evidence indicates possible metabolic interactions
• Schedule Y emphasizes the need for evaluating interactions for fixed-dose combinations (FDCs)

Types of DDI Studies

1. Inhibition Studies

Assess whether the investigational drug inhibits enzymes or transporters involved in the metabolism of other drugs.

• Example: New drug inhibits CYP3A4 and increases exposure to midazolam

2. Induction Studies

Evaluate whether the investigational drug induces metabolizing enzymes, reducing the effect of co-administered drugs.

• Example: New drug induces CYP1A2 and lowers caffeine levels

3. Substrate Studies

Study whether the investigational drug is a substrate affected by inhibitors or inducers.

• Example: Ketoconazole inhibits metabolism of the new drug (victim DDI)

4. Transporter-Based Studies

Focus on P-glycoprotein (P-gp), BCRP, OATP, and other transport proteins that affect drug absorption and elimination.

• Example: Verapamil affects new drug via P-gp inhibition

Study Designs for DDI in Phase 1

1. Crossover Design

• Each subject receives both treatments: drug alone and drug with perpetrator
• Requires washout period
• Reduces inter-subject variability

2. Fixed-Sequence Design

• Perpetrator given first to reach steady state, then new drug added
• Common when enzyme induction/inhibition needs time to manifest

3. Parallel Group Design

• Used when crossover is not feasible (e.g., long half-life drugs)
• Larger sample size due to between-group variability

Probe Substrates and Inhibitors

Standard Probe Substrates

Enzyme	Probe Substrate
CYP3A4	Midazolam
CYP2D6	Dextromethorphan
CYP2C9	Warfarin
CYP2C19	Omeprazole
P-gp	Digoxin

Strong Inhibitors and Inducers

Effect	Examples
Strong CYP3A4 Inhibitor	Ketoconazole, Itraconazole
Strong CYP3A4 Inducer	Rifampin, Carbamazepine

Endpoints and PK Evaluation

• Primary PK: Cmax, AUC_0–t, AUC_0–∞
• Secondary: Tmax, t_½, CL/F, metabolite ratio

Statistical Interpretation

• Use geometric mean ratios (GMR) and 90% confidence intervals
• DDI significance based on whether 90% CI falls outside 80–125%
• Stronger deviation = clinically meaningful interaction

Regulatory Labeling Based on DDI

• Label Sections: Drug Interactions, Dosage and Administration, Warnings
• Typical Statements: “Avoid coadministration with strong CYP3A4 inhibitors,” “Reduce dose when coadministered with rifampin”
• Examples: FDA requires boxed warnings when interactions may cause life-threatening events

PBPK Modeling in DDI

• Used to simulate and predict DDI without full clinical trials
• Supports waivers or targeted studies
• Models must be validated with in vitro and clinical data

Best Practices for Conducting DDI Studies

• Start with strong in vitro metabolism and transporter studies
• Select appropriate probe and perpetrator drugs based on metabolic pathways
• Use validated assays and bioanalytical methods
• Clearly define decision rules and dose modification plans
• Include a robust Statistical Analysis Plan (SAP)